These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 3409330)
41. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential. Clémenceau B; Vivien R; Pellat C; Foss M; Thibault G; Vié H MAbs; 2013; 5(4):587-94. PubMed ID: 23770975 [TBL] [Abstract][Full Text] [Related]
42. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells. Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424 [TBL] [Abstract][Full Text] [Related]
44. Tumor-cell killing by MAbs against fucosyl GM1, a ganglioside antigen associated with small-cell lung carcinoma. Brezicka FT; Holmgren J; Kalies I; Lindholm L Int J Cancer; 1991 Dec; 49(6):911-8. PubMed ID: 1660040 [TBL] [Abstract][Full Text] [Related]
45. Macrophage colony-stimulating factor enhancement of antibody-dependent cellular cytotoxicity against human colon carcinoma cells. Qi CF; Nieroda C; De Filippi R; Greiner JW; Correale P; Schlom J; Tsang KY Immunol Lett; 1995; 47(1-2):15-24. PubMed ID: 8537095 [TBL] [Abstract][Full Text] [Related]
46. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Schlesinger JJ; Foltzer M; Chapman S Virology; 1993 Jan; 192(1):132-41. PubMed ID: 8517015 [TBL] [Abstract][Full Text] [Related]
47. Apparent sensitivity of human K lymphocytes to the spatial orientation and organization of target cell-bound antibodies as measured by the efficiency of antibody-dependent cellular cytotoxicity (ADCC). Christiaansen JE; Burnside SS; Sears DW J Immunol; 1987 Apr; 138(7):2236-43. PubMed ID: 3549899 [TBL] [Abstract][Full Text] [Related]
48. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies. Helfand SC; Hank JA; Gan J; Sondel PM Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851 [TBL] [Abstract][Full Text] [Related]
49. Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies. Vuist WM; van Buitenen F; Hekman A; Melief CJ Cancer Res; 1990 Sep; 50(18):5767-72. PubMed ID: 1697500 [TBL] [Abstract][Full Text] [Related]
51. Coordinator's report: an assessment of the functional activity of human Rh monoclonal antibodies after their evaluation by nine laboratories. Kumpel BM Transfus Clin Biol; 1996; 3(6):439-52. PubMed ID: 9018805 [TBL] [Abstract][Full Text] [Related]
52. Effector characteristics of the IgG3 murine monoclonal antibody 113F1. Weiner LM; Zarou CM; O'Brien J; Ring D J Biol Response Mod; 1989 Jun; 8(3):227-37. PubMed ID: 2787391 [TBL] [Abstract][Full Text] [Related]
53. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18. Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646 [TBL] [Abstract][Full Text] [Related]
54. Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in mice. Yuan RR; Spira G; Oh J; Paizi M; Casadevall A; Scharff MD Infect Immun; 1998 Mar; 66(3):1057-62. PubMed ID: 9488395 [TBL] [Abstract][Full Text] [Related]
55. Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation. Johnson WJ; Steplewski Z; Matthews TJ; Hamilton TA; Koprowski H; Adams DO J Immunol; 1986 Jun; 136(12):4704-13. PubMed ID: 3711663 [TBL] [Abstract][Full Text] [Related]
56. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen. Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315 [TBL] [Abstract][Full Text] [Related]
57. Complement and cellular cytotoxicity in antibody therapy of cancer. Wang SY; Weiner G Expert Opin Biol Ther; 2008 Jun; 8(6):759-68. PubMed ID: 18476787 [TBL] [Abstract][Full Text] [Related]
58. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies. Kawase I; Komuta K; Ogura T; Fujiwara H; Hamaoka T; Kishimoto S Cancer Res; 1985 Apr; 45(4):1663-8. PubMed ID: 3978634 [TBL] [Abstract][Full Text] [Related]
59. Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma. Rue SM; Eckelman BP; Efe JA; Bloink K; Deveraux QL; Lowery D; Nasoff M Vet Immunol Immunopathol; 2015 Apr; 164(3-4):148-59. PubMed ID: 25764941 [TBL] [Abstract][Full Text] [Related]
60. Characterization of immunoglobulin class and subclass responses in secondary aborter sera. Torry DS; McIntyre JA; McConnachie PR J Reprod Immunol; 1987 Jan; 10(1):33-42. PubMed ID: 3585863 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]